Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Janux Therapeutics Inc (JANX)
NASDAQ:JANX
Holding JANX?
Track your performance easily
JANX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.65 - $65.60
Previous Close$54.39
Volume838.42K
Average Volume (3M)586.44K
Market Cap
$2.84B
Enterprise Value$2.21B
Total Cash (Recent Filing)$646.29M
Total Debt (Recent Filing)$23.82M
Price to Earnings (P/E)―
Beta2.59
Next Earnings
Nov 05, 2024EPS Estimate
-$0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding52,164,498
10 Day Avg. Volume661,637
30 Day Avg. Volume586,440
Standard Deviation0.78
R-Squared0.05
Alpha0.09
Financial Highlights & Ratios
Price to Book (P/B)4.31
Price to Sales (P/S)187.56
Price to Cash Flow (P/CF)-70.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue146.41
Enterprise Value/Gross Profit274.00
Enterprise Value/Ebitda-56.93
Forecast
1Y Price Target
$67.67Price Target Upside21.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
Janux Therapeutics Inc News
PremiumCompany Announcements
Janux Therapeutics Announces Board of Directors Reshuffle
Bulls Say, Bears Say
Bulls Say
Clinical DataInitial data from a Phase 1 trial demonstrated monotherapy efficacy in late line patients and better safety profile compared to Novartis' Pluvicto.
Clinical DevelopmentFebruary’s interim phase 1a data for JANX007 suggest it has a high likelihood of becoming an innovative and differentiated therapy for the unmet need in prostate cancer.
Financial PerformanceThe company reported total revenues of approximately $8.9M and a net loss of $0.11 per share, compared to the consensus estimates of total revenues of $0.77M and a net loss of $0.31 per share.
Bears Say
Clinical Trial ResultsAmgen's STEAP1 asset showed markedly reduced efficacy and poorer safety at ESMO.
Data Update UncertaintyUncertain if median duration of response will be presented in the 2H24 data update.
Safety Concerns≥Grade 3 ILD events are one of the main concerns with J&J's data.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
JANX FAQ
What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $5.65 and its highest was $65.60 in the past 12 months.
What is Janux Therapeutics Inc’s market cap?
Currently, no data Available
When is Janux Therapeutics Inc’s upcoming earnings report date?
Janux Therapeutics Inc’s upcoming earnings report date is Nov 05, 2024 which is today.
How were Janux Therapeutics Inc’s earnings last quarter?
Janux Therapeutics Inc released its earnings results on Aug 07, 2024. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.311 by $0.201.
Is Janux Therapeutics Inc overvalued?
According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
Does Janux Therapeutics Inc pay dividends?
Janux Therapeutics Inc does not currently pay dividends.
What is Janux Therapeutics Inc’s EPS estimate?
Janux Therapeutics Inc’s EPS estimate is -$0.33.
How many shares outstanding does Janux Therapeutics Inc have?
Janux Therapeutics Inc has 52,164,497 shares outstanding.
What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
Janux Therapeutics Inc reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.311. Following the earnings report the stock price went up 3.4%.
Which hedge fund is a major shareholder of Janux Therapeutics Inc?
Among the largest hedge funds holding Janux Therapeutics Inc’s share is RA Capital Management. It holds Janux Therapeutics Inc’s shares valued at 384M.
---
Janux Therapeutics Inc Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.67 (21.12% Upside)
$67.67 (21.12% Upside)
Blogger Sentiment
Bullish
JANX Sentiment 80%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 66.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $72.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 3.9%
Last 30 Days ▲ 3.9%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
747.19%
12-Months-Change
Fundamentals
Return on Equity
-9.20%
Trailing 12-Months
Asset Growth
102.46%
Trailing 12-Months
Company Description
Janux Therapeutics Inc
Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.
---
JANX Stock 12 Month Forecast
Average Price Target
$67.67
▲(21.12% Upside)
Technical Analysis
Nurix Therapeutics
―
RAPT Therapeutics
―
Bicycle Therapeutics
―
Fulcrum Therapeutics
―
Best Analysts Covering JANX
1 Year
1 Year Success Rate
5/5 ratings generated profit
1 Year Average Return
+15.08%
reiterated a buy rating 6 days ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +15.08% per trade.
---